vs
Side-by-side financial comparison of ROCKWELL MEDICAL, INC. (RMTI) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
ROCKWELL MEDICAL, INC. is the larger business by last-quarter revenue ($18.3M vs $11.5M, roughly 1.6× TRANSACT TECHNOLOGIES INC). On growth, TRANSACT TECHNOLOGIES INC posted the faster year-over-year revenue change (11.9% vs -25.6%). ROCKWELL MEDICAL, INC. produced more free cash flow last quarter ($2.2M vs $589.0K). Over the past eight quarters, TRANSACT TECHNOLOGIES INC's revenue compounded faster (3.5% CAGR vs -10.1%).
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
RMTI vs TACT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.3M | $11.5M |
| Net Profit | $-554.0K | — |
| Gross Margin | 21.1% | 47.6% |
| Operating Margin | -2.2% | -10.1% |
| Net Margin | -3.0% | — |
| Revenue YoY | -25.6% | 11.9% |
| Net Profit YoY | 26.7% | — |
| EPS (diluted) | $-0.01 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.3M | $11.5M | ||
| Q3 25 | $15.9M | $13.2M | ||
| Q2 25 | $16.1M | $13.8M | ||
| Q1 25 | $18.9M | $13.1M | ||
| Q4 24 | $24.7M | $10.2M | ||
| Q3 24 | $28.3M | $10.9M | ||
| Q2 24 | $25.8M | $11.6M | ||
| Q1 24 | $22.7M | $10.7M |
| Q4 25 | $-554.0K | — | ||
| Q3 25 | $-1.8M | $15.0K | ||
| Q2 25 | $-1.5M | $-143.0K | ||
| Q1 25 | $-1.5M | $19.0K | ||
| Q4 24 | $-756.0K | — | ||
| Q3 24 | $1.7M | $-551.0K | ||
| Q2 24 | $343.0K | $-319.0K | ||
| Q1 24 | $-1.7M | $-1.0M |
| Q4 25 | 21.1% | 47.6% | ||
| Q3 25 | 14.3% | 49.8% | ||
| Q2 25 | 15.6% | 48.2% | ||
| Q1 25 | 16.1% | 48.7% | ||
| Q4 24 | 14.7% | 44.2% | ||
| Q3 24 | 22.0% | 48.1% | ||
| Q2 24 | 17.6% | 52.7% | ||
| Q1 24 | 13.5% | 52.6% |
| Q4 25 | -2.2% | -10.1% | ||
| Q3 25 | -9.9% | 0.1% | ||
| Q2 25 | -8.4% | -1.9% | ||
| Q1 25 | -7.2% | -0.1% | ||
| Q4 24 | -2.1% | -10.3% | ||
| Q3 24 | 6.8% | -7.7% | ||
| Q2 24 | 2.0% | -3.8% | ||
| Q1 24 | -5.8% | -12.2% |
| Q4 25 | -3.0% | — | ||
| Q3 25 | -11.0% | 0.1% | ||
| Q2 25 | -9.3% | -1.0% | ||
| Q1 25 | -8.0% | 0.1% | ||
| Q4 24 | -3.1% | — | ||
| Q3 24 | 5.9% | -5.1% | ||
| Q2 24 | 1.3% | -2.8% | ||
| Q1 24 | -7.6% | -9.7% |
| Q4 25 | $-0.01 | $-0.11 | ||
| Q3 25 | $-0.05 | $0.00 | ||
| Q2 25 | $-0.05 | $-0.01 | ||
| Q1 25 | $-0.04 | $0.00 | ||
| Q4 24 | $-0.02 | $-0.80 | ||
| Q3 24 | $0.04 | $-0.06 | ||
| Q2 24 | $0.01 | $-0.03 | ||
| Q1 24 | $-0.06 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.7M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $37.0M | $31.1M |
| Total Assets | $57.1M | $44.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.7M | $20.4M | ||
| Q3 25 | $13.6M | $20.0M | ||
| Q2 25 | $12.5M | $17.7M | ||
| Q1 25 | $11.4M | $14.2M | ||
| Q4 24 | $15.7M | $14.4M | ||
| Q3 24 | $12.3M | $11.3M | ||
| Q2 24 | $11.9M | $11.1M | ||
| Q1 24 | $6.6M | $10.6M |
| Q4 25 | $37.0M | $31.1M | ||
| Q3 25 | $37.0M | $31.8M | ||
| Q2 25 | $30.4M | $31.3M | ||
| Q1 25 | $31.5M | $30.9M | ||
| Q4 24 | $32.6M | $30.6M | ||
| Q3 24 | $29.1M | $38.4M | ||
| Q2 24 | $23.5M | $38.5M | ||
| Q1 24 | $20.6M | $38.6M |
| Q4 25 | $57.1M | $44.8M | ||
| Q3 25 | $57.5M | $45.0M | ||
| Q2 25 | $52.6M | $44.5M | ||
| Q1 25 | $54.0M | $44.2M | ||
| Q4 24 | $59.2M | $44.0M | ||
| Q3 24 | $57.1M | $50.5M | ||
| Q2 24 | $53.0M | $50.4M | ||
| Q1 24 | $50.7M | $51.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.3M | $609.0K |
| Free Cash FlowOCF − Capex | $2.2M | $589.0K |
| FCF MarginFCF / Revenue | 12.0% | 5.1% |
| Capex IntensityCapex / Revenue | 0.5% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-1.2M | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.3M | $609.0K | ||
| Q3 25 | $-1.3M | $3.6M | ||
| Q2 25 | $1.8M | $3.6M | ||
| Q1 25 | $-3.5M | $-161.0K | ||
| Q4 24 | $865.0K | $2.4M | ||
| Q3 24 | $4.3M | $327.0K | ||
| Q2 24 | $1.4M | $636.0K | ||
| Q1 24 | $-2.4M | $-1.5M |
| Q4 25 | $2.2M | $589.0K | ||
| Q3 25 | $-1.5M | $3.6M | ||
| Q2 25 | $1.7M | $3.6M | ||
| Q1 25 | $-3.5M | $-171.0K | ||
| Q4 24 | $470.0K | $2.4M | ||
| Q3 24 | $4.1M | $259.0K | ||
| Q2 24 | $1.2M | $499.0K | ||
| Q1 24 | $-2.5M | $-1.6M |
| Q4 25 | 12.0% | 5.1% | ||
| Q3 25 | -9.6% | 27.1% | ||
| Q2 25 | 10.5% | 25.9% | ||
| Q1 25 | -18.8% | -1.3% | ||
| Q4 24 | 1.9% | 23.2% | ||
| Q3 24 | 14.4% | 2.4% | ||
| Q2 24 | 4.5% | 4.3% | ||
| Q1 24 | -11.1% | -14.9% |
| Q4 25 | 0.5% | 0.2% | ||
| Q3 25 | 1.4% | 0.5% | ||
| Q2 25 | 1.0% | 0.1% | ||
| Q1 25 | 0.3% | 0.1% | ||
| Q4 24 | 1.6% | 0.1% | ||
| Q3 24 | 0.7% | 0.6% | ||
| Q2 24 | 1.1% | 1.2% | ||
| Q1 24 | 0.6% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 4.20× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |
TACT
Segment breakdown not available.
